Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$12.98 USD
+0.12 (0.93%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $12.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.98 USD
+0.12 (0.93%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $12.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Summit Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Summit Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Can the Rally in Summit Therapeutics Shares Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Summit Therapeutics.
Top Ranked Momentum Stocks to Buy for October 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 22nd
Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply
by Zacks Equity Research
Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.
New Strong Sell Stocks for December 19th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Catalent (CTLT) Catches Eye: Stock Jumps 5.2%
by Zacks Equity Research
Catalent (CTLT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zogenix's Epilepsy Candidate Successful in Phase III Study
by Zacks Equity Research
Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
KemPharm Stock Down Despite Positive Data on ADHD Candidate
by Zacks Equity Research
KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.
Summit Therapeutics Enters Oversold Territory
by Zacks Equity Research
Summit Therapeutics Enters Oversold Territory
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.
M&A, Innovation & New Drugs to Drive Pharma Stocks
by Zacks Equity Research
The new tax law, which cuts the corporate tax rate from 35% to 21% and encourages companies to bring back cash held overseas at a one-time tax rate of 10%, is expected to spur merger activity.
Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session
by Zacks Equity Research
Shares of Apricus Biosciences (APRI) rose about 9% yesterday.
Sarepta's Golodirsen Positive in DMD Study, Shares Soar
by Zacks Equity Research
Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.
Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.
Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.
Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
by Zacks Equity Research
Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.
Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
by Zacks Equity Research
Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.
Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss
by Zacks Equity Research
Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.
Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.
Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered
by Zacks Equity Research
Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.
Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.
Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.
Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Spectrum Pharmaceuticals. (SPPI) reported narrower than expected sales and also beat sales expectations. The shares of the company were up due to positive pipeline updates.